CREATE Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable, off-the-shelf treatments for cancer, autoimmunity, and fibrosis
Location: United States
Total raised: $122M
Investors 1
| Date | Name | Website |
| 07.11.2025 | Newpath Ma... | newpath.pa... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.05.2026 | Series B | $122M | ARCH Ventu... |
Mentions in press and media 4
| Date | Title | Description |
| 14.05.2026 | Create Medicines Raises $122M in Series B Funding | Create Medicines, Inc., a Cambridge, Massachusetts-based developer of in vivo immune programming and mRNA-LNP cell therapies, raised $122m in Series B funding. The round was co-led by existing investors Newpath Partners, ARCH Venture Partne... |
| 14.05.2026 | Top Startup and Tech Funding News – May 14, 2025 | It’s Thursday, May 14, 2026, and we’re back with today’s top startup and tech funding news. Today’s rounds show investors leaning into platforms that sit close to real infrastructure: in vivo cell therapy, AI data center cooling, embedded b... |
| 14.05.2026 | Create Medicines fashions $122M fundraise for in vivo CAR-T dreams | As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back its early pipeline of autoimmune and cancer candidates. Originally launched in 2021 as Myeloid Therapeutics by cell ... |
| 14.05.2026 | CREATE Medicines Nabs $122M Series B | CAMBRIDGE, MA, CREATE Medicines, a clinical-stage biotechnology company pioneering in vivo immune programming, today announced the closing of its $122 million Series B funding round. >> Click here for more funding data on CREATE Medi... |